Focus: Ossium Health is a Series A biotechnology company focused on bone marrow-derived stem cell therapies for cell therapy and musculoskeletal indications. With 201-500 employees based in Indianapolis, the company is early-stage with 11 active clinical trials spanning multiple therapeutic areas.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Best for early-career scientists, clinical ops, and commercial strategists seeking equity upside and first-mover advantage in advanced cell therapy, but expect extended pre-commercial runway and cash uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ossium Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ossium Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo